There are currently 603 clinical trials in Omaha, Nebraska looking for participants to engage in research studies. Trials are conducted at various facilities, including University of Nebraska Medical Center, Creighton University Medical Center, Nebraska Methodist Hospital and Alegent Health Bergan Mercy Medical Center. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
A Study Evaluating the Efficacy of Budesonide, Glycopyrronium and Formoterol Fumarate Metered Dosed Inhaler on Cardiopulmonary Outcomes in Chronic Obstructive Pulmonary Disease
NCT06283966
Recruiting
This study will evaluate the effect of triple ICS/LAMA/LABA therapy with BGF MDI 320/14.4/9.6 μg on cardiopulmonary outcomes relative to LAMA/LABA therapy with GFF MDI 14.4/9.6 μg in a population with COPD and elevated cardiopulmonary risk.
Gender:
All
Ages:
Between 40 years and 80 years
Trial Updated:
03/11/2024
Locations: Research Site, Omaha, Nebraska
Conditions: COPD (Chronic Obstructive Pulmonary Disease)
Register for Updates
Dose Escalation/ Expansion Study of CA-4948 as Monotherapy in Patients With AML or MDS
NCT04278768
Recruiting
This is a multicenter, open-label, Phase 1/2a dose escalation and expansion study of orally administered emavusertib (CA-4948) monotherapy in adult patients with Acute Myelogenous Leukemia (AML) or high risk Myelodysplastic Syndrome (MDS). Patients enrolling in the Phase 1 portion of the study must meet one of the following criteria prior to consenting to the study: R/R AML with FLT3 mutations who have been previously treated with a FLT3 inhibitor R/R AML with spliceosome mutations of SF3B1 or... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
03/08/2024
Locations: Oncology Hematology West, PC dba Nebraska Cancer Specialists, Omaha, Nebraska
Conditions: Acute Myelogenous Leukemia, Myelodysplastic Syndrome
Register for Updates
A Study of Temodar With Abexinostat (PCI-24781) for Patients With Recurrent Glioma
NCT05698524
Recruiting
The goal of this clinical trial is to learn about treatment for a type of brain cancer called glioma. This clinical trial is for people with glioma who have been cancer-free for a period of time but their cancer has come back. The primary goals of this clinical trial are the following: To determine the recommended dose of PCI-24781/Abexinostat with metronomic temozolomide To evaluate side effects associated with using PCI-24781/Abexinostat with metronomic temozolomide
Gender:
All
Ages:
19 years and above
Trial Updated:
03/08/2024
Locations: University of Nebraska Medical Center, Omaha, Nebraska
Conditions: Recurrent High Grade Glioma, Anaplastic Astrocytoma, Anaplastic Oligodendroglioma, Glioblastoma, Gliosarcoma
Register for Updates
Hyaluronidase Via LADD Scleroderma-induced Microstomia
NCT05995626
Recruiting
Two treatment methods, ablative carbon dioxide (CO2) laser and intradermal hyaluronidase, will be combined to maximize the beneficial potential of each. Laser-assisted drug delivery (LADD) has been shown to be effective for the administration of medications in diverse skin diseases but not previously reported for the treatment of scleroderma-induced microstomia. By using this laser technique, the investigator can reduce the pain of typical hyaluronidase injections and reap the therapeutic benefi... Read More
Gender:
All
Ages:
19 years and above
Trial Updated:
03/06/2024
Locations: University of Nebraska Medical Center, Lauritzen Outpatient Center, Omaha, Nebraska +1 locations
Conditions: Microstomia, Scleroderma
Register for Updates
FT522 With Rituximab in Relapsed/Refractory B-Cell Lymphoma (FT522-101)
NCT05950334
Recruiting
This is a phase 1 study of FT522 administered with rituximab in participants with relapsed/refractory B-cell lymphoma (R/R BCL). The primary objectives of the study are to evaluate the safety and tolerability of FT522 in combination with rituximab, and to determine the recommended phase 2 dose (RP2D) of FT522 in combination with rituximab; each objective will be assessed with or without conditioning chemotherapy.
Gender:
All
Ages:
18 years and above
Trial Updated:
03/06/2024
Locations: University of Nebraska Medical Center, Omaha, Nebraska
Conditions: Relapsed/Refractory B-Cell Lymphoma
Register for Updates
FT819 in Moderate to Severe Active Systemic Lupus Erythematosus
NCT06308978
Recruiting
This is a phase 1 study designed to evaluate the safety, pharmacokinetics (PK), and anti-B-cell activity of FT819 following conditioning chemotherapy in participants with moderate to severe active systemic lupus erythematosus (SLE). The study will consist of a dose-escalation stage, followed by an expansion stage to further evaluate the safety and activity of FT819.
Gender:
All
Ages:
18 years and above
Trial Updated:
03/06/2024
Locations: University of Nebraska Medical Center, Omaha, Nebraska
Conditions: Systemic Lupus Erythematosus
Register for Updates
Robot Rehab: AAI With Robot During Inpatient Pediatric Rehab
NCT05275543
Recruiting
The purpose of this study is to: Aim 1: Evaluate the feasibility [consent and refusal rates, attrition rates, length, and number of completed therapy sessions], and acceptability [interviews with children and guardians, overall patient and guardian satisfaction] during inpatient physical therapy (PT) and occupational therapy (OT) sessions. Hypothesis: Animal-assisted interaction (AAI) with Paro, a robotic baby harp seal, during pediatric inpatient PT/OT sessions will be feasible and acceptable.... Read More
Gender:
All
Ages:
Between 5 years and 18 years
Trial Updated:
03/04/2024
Locations: Children's Hosptial and Medical Center, Omaha, Nebraska
Conditions: Pediatric ALL, Child, Hospitalized, Physical Therapy Modalities, Occupational Therapy, Animal Assisted Therapy
Register for Updates
Understanding the Long-term Impact of COVID on Children and Families
NCT05172011
Recruiting
This is a combined retrospective and prospective, longitudinal, observational meta-cohort of individuals age 0-25 years who will enter the cohort with and without SARS-CoV-2 infection at varying stages before and after infection. Individuals with and without SARS-CoV-2 infection and with or without PASC symptoms will be followed to identify risk factors and occurrence of PASC. This study will be conducted in the United States and participants will be recruited through inpatient, outpatient, and... Read More
Gender:
All
Ages:
25 years and below
Trial Updated:
03/04/2024
Locations: University Of Nebraska Medical Center, Omaha, Nebraska
Conditions: SARS-CoV-2 Infection
Register for Updates
Development of Functional Spatial Hearing in Reverberation
NCT05815537
Recruiting
The goal of the clinical trial study (Phase 0) is to map out the developmental trajectory of functional spatial hearing abilities in reverberant environments for children with normal hearing between the ages of 6 and 18 years, and to understand the inter-relationships between the three perceptual abilities: auditory object size formation, spatial acuity, and spatial unmasking during typical development. Children are asked to perform psychoacoustic tasks when the auditory stimuli are processed to... Read More
Gender:
All
Ages:
Between 6 years and 30 years
Trial Updated:
03/01/2024
Locations: Boys Town National Research Hospital, Omaha, Nebraska
Conditions: Spatial Hearing Development
Register for Updates
Dose-finding, Pharmacokinetics, and Safety of VABOMERE in Pediatric Subjects With Bacterial Infections
NCT02687906
Recruiting
A single dose infusion of Vabomere (meropenem-vaborbactam) is being tested for dose-finding, pharmacokinetics, safety, and tolerability in pediatric subjects from birth to less than 18 years of age with serious bacterial infections
Gender:
All
Ages:
17 years and below
Trial Updated:
03/01/2024
Locations: University of Nebraska Medical Center, Omaha, Nebraska
Conditions: Bacterial Infections
Register for Updates
Anti-tumour Activity of (177Lu) rhPSMA-10.1 Injection
NCT05413850
Recruiting
To determine the dose, safety, radiation dosimetry and efficacy of 177Lu-rhPSMA-10.1 in participants with PSMA-expressing metastatic castrate resistant prostate cancer.
Gender:
Male
Ages:
18 years and above
Trial Updated:
03/01/2024
Locations: XCancer Omaha / Urology Cancer Center, Omaha, Nebraska
Conditions: Prostate Cancer, Metastatic Castration-resistant Prostate Cancer, mCRPC, Urogenital Neoplasms, Prostatic Neoplasms, Prostatic Diseases
Register for Updates
Open-Label, Dose-Finding, Pharmacokinetics, Safety and Tolerability Study of Oritavancin in Pediatric Patients With Suspected or Confirmed Bacterial Infections
NCT02134301
Recruiting
The purpose of this Phase 1 trial is to evaluate the pharmacokinetics, safety and tolerability of oritavancin in patients <18 years old with a confirmed or suspected bacterial infection.
Gender:
All
Ages:
18 years and below
Trial Updated:
03/01/2024
Locations: University of Nebraska Medical Center, Omaha, Nebraska
Conditions: Gram Positive Bacterial Infections
Register for Updates